[{"id":"68d8ce34-194a-45f2-9e93-7c94e62c1815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02356159","created_at":"2021-01-18T11:12:44.041Z","updated_at":"2024-07-02T16:34:36.807Z","phase":"Phase 1/2","brief_title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT02356159","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/24/2015","start_date":" 09/24/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-10"},{"id":"7228addd-99a0-4c5e-a6f3-befe14f6f6de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800210","created_at":"2023-04-05T14:03:37.666Z","updated_at":"2024-07-02T16:35:05.164Z","phase":"Phase 2","brief_title":"Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","source_id_and_acronym":"NCT05800210","lead_sponsor":"University of Florida","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • CBL mutation • Chr t(9;11)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CBL mutation • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2024","start_date":" 05/03/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-08"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"},{"id":"236e87b1-3a45-4987-8e83-19ff77105b1b","acronym":"SU-09142011-8407","url":"https://clinicaltrials.gov/study/NCT01660607","created_at":"2021-01-18T07:10:13.721Z","updated_at":"2024-07-02T16:35:17.716Z","phase":"Phase 1/2","brief_title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","source_id_and_acronym":"NCT01660607 - SU-09142011-8407","lead_sponsor":"Everett Meyer","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-02-26"},{"id":"c80dda17-2bdc-4783-9fe5-a49313fb46d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05139004","created_at":"2021-12-01T15:53:46.640Z","updated_at":"2024-07-02T16:35:21.820Z","phase":"Phase 1","brief_title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05139004","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • NPM1 • IL2RA • ISG20","pipe":" | ","alterations":" MLL rearrangement • IL2RA expression • Chr t(9;11)","tags":["FLT3 • NPM1 • IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • IL2RA expression • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-01-30"},{"id":"8d95cfee-d199-493c-bd71-e53e5a126739","acronym":"","url":"https://clinicaltrials.gov/study/NCT02446964","created_at":"2021-01-18T11:44:09.525Z","updated_at":"2024-07-02T16:35:24.729Z","phase":"Phase 1","brief_title":"Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia","source_id_and_acronym":"NCT02446964","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" MLL rearrangement • Chr t(9;11)","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/25/2015","start_date":" 06/25/2015","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2024","study_completion_date":" 06/15/2024","last_update_posted":"2024-01-03"},{"id":"7d36623f-54df-47be-a4e4-1dee851f8906","acronym":"COALA","url":"https://clinicaltrials.gov/study/NCT05499611","created_at":"2022-11-08T19:21:31.726Z","updated_at":"2024-07-02T16:35:31.379Z","phase":"","brief_title":"Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT05499611 - COALA","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA","pipe":" | ","alterations":" Chr del(5q) • Chr t(9;11)","tags":["TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/27/2023","start_date":" 01/27/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-10-27"},{"id":"b119b2d5-0346-413e-8687-8b862f5843de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04099966","created_at":"2021-01-18T20:03:29.576Z","updated_at":"2024-07-02T16:35:31.618Z","phase":"Phase 2","brief_title":"AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion","source_id_and_acronym":"NCT04099966","lead_sponsor":"Mitchell Cairo","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • Chr t(9;11)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-26"},{"id":"1ec7ade3-a1ff-44d4-b7ca-e3d08c57d7b8","acronym":"IM-TMI","url":"https://clinicaltrials.gov/study/NCT04187105","created_at":"2021-01-18T20:24:37.787Z","updated_at":"2024-07-02T16:35:37.511Z","phase":"Phase 2","brief_title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","source_id_and_acronym":"NCT04187105 - IM-TMI","lead_sponsor":"University of Illinois at Chicago","biomarkers":" RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)","tags":["RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-09-11"},{"id":"55ae7010-7764-4de2-8cd8-29528a06d55c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03121014","created_at":"2021-01-18T15:22:34.706Z","updated_at":"2024-07-02T16:35:44.013Z","phase":"Phase 2","brief_title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","source_id_and_acronym":"NCT03121014","lead_sponsor":"University of Illinois at Chicago","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 04/24/2024","primary_completion_date":" 04/24/2024","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2023-07-04"},{"id":"8f85763f-e649-4c88-96b6-c0ae0f05eac2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744223","created_at":"2021-01-18T07:37:40.124Z","updated_at":"2024-07-02T16:36:07.432Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","source_id_and_acronym":"NCT01744223","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 10/09/2019","primary_completion_date":" 10/09/2019","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2022-07-12"}]